Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




New Treatment for Bone Bleeding

By HospiMedica staff writers
Posted on 29 Nov 2006
A new treatment for bone bleeding offers an alternative to beeswax, an American Civil War-era battlefield remedy.

Researchers from the University of Southern California (Los Angeles, USA) have developed a new synthetic copolymer, called Ostene, a bone hemostasis material that is designed to stop bone bleeding in orthopedic, cardiac, and neurospinal surgery without the harmful side effects associated with commonly used beeswax.

Ostene acts like a mechanical barrier, stopping bone bleeding instantaneously, but unlike beeswax, it does so without interfering with bone healing or causing inflammation of the surrounding soft tissue. More...
Made of water-soluble alkylene oxide copolymers, Ostene is completely synthetic and does not react with the body's chemistry, reducing the risk of infection and allergic reactions. It allows the bone to heal without causing an inflammatory response, and is eliminated from the body within 48 hours after surgery. The product has been approved by the U.S. Food and Drug Administration (FDA).

Ostene is manufactured by Ceremed (Los Angeles, CA, USA).

Beeswax remains at the surgical site indefinitely and may induce an inflammatory response even 10 years after surgery. The number of bacteria needed to produce a bone infection is reduced 10,000 times in the presence of beeswax, and it also prevents new bone formation and bone union. Once covered with beeswax, a bone will not regenerate.



Related Links:
University of Southern California
Ceremed

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.